Timber Pharmaceuticals Inc

Timber Pharmaceuticals — Investor Presentation (September 2020)

18 slides from Timber Pharmaceuticals's investor presentation, Sep 16, 2020

  1. Slide 1: Building Bridges in Medical Dermatology

    Building Bridges in Medical Dermatology Investor Presentation NYSE American: TMBR September 2020

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitute “forward - looking s

  3. Slide 3: Introducing Timber Pharmaceuticals

    3 Introducing Timber Pharmaceuticals Timber Pharmaceuticals is building an orphan dermatology company that focuses on mitigating the cost, risk, and time of drug development by leveraging the Orphan Drug pathway for conditions with no FDA Approved treatments. The company’s investigational therapies

  4. Slide 4: Investment Highlights

    4 Investment Highlights • Positioned to become a leading Dermatology company with a focus on orphan diseases, led by a management team with a proven track record in development and commercialization • High potential, late stage, low risk multi - product candidate pipeline • Proven clinical Proof of

  5. Slide 5: Timber's Focused Strategy

    5 Timber’s Focused Strategy • Focused on mitigating the cost, risk, and time of drug development while retaining earnings potential • Based on three key tenets: • Emphasis on compounds with broad and proven mechanisms of action across many dermatologic conditions • Differentiation of the drug produc

  6. Slide 6: Timber Business Model

    6 Timber Business Model • Focused on Orphan Drug Indications and Leveraging the 505(b)(2) pathway • Orphan Drugs • Timber will be first to market by pursuing conditions for which there are no current FDA approved treatments • Requires smaller and less costly drug trials with greater flexibility from

  7. Slide 7: Strategically Building Pipeline in Rare Dermatologic Disease

    7 Strategically Building Pipeline in Rare Dermatologic Disease NYSE American: TMBR

  8. Slide 8: Life Cycle Management

    8 Life Cycle Management All products have potential follow - on indications in significant dermatology markets Severe Acne Port Wine Stains Hypertrophic/Keloid Scars TMB - 001 TMB - 002 TMB - 003 Sturge - Weber Syndrome Darier’s Disease Scarring Alopecia Sebaceous Hyperplasia NYSE American: TMBR

  9. Slide 9: TMB-001 for Congenital Ichthyosis

    9 TMB - 001 for Congenital Ichthyosis A rare disorder of keratinization affecting ~ 80,000 people in the U.S. (>1.5 million globally) Prevalence • X - Linked Ichthyosis has a prevalence of 1:2,000 - 1:6,000 males • Lamellar Ichthyosis has a prevalence of 1:100,000 - 200,000 Quality of life is signif

  10. Slide 10: TMB-001 Topical Isotretinoin in CI

    10 Isotretinoin is widely viewed as the most effective therapy for several skin conditions, including ichthyosis, but it is only available orally, where high dose, chronic oral therapy cannot be tolerated due to systemic toxicity TMB - 001 utilizes proprietary IPEG™ delivery system to target isotret

  11. Slide 11: TMB for Facial Angiofibromas in Tuberous Sclerosis Complex

    11 TMB - 002 for Facial Angiofibromas in Tuberous Sclerosis Complex TSC is a multisystem genetic disorder affecting approximately 50,000 people in the US TSC is caused by the unregulated activation of the mammalian target of rapamycin (mTOR) pathway, resulting in the growth of hamartomas in multiple

  12. Slide 12: TMB Topical Rapamycin (Pascomer)

    12 TMB - 002 Topical Rapamycin (Pascomer®) Potentially the First Commercially Available, High - Quality Topical Formulation of Rapamycin with Broad Access Proprietary topical formulation of rapamycin (1.0%, 0.5%, and 0.1%) • Additional 5% strength assessed in preclinical toxicity studies Utilizes tr

  13. Slide 13: Anticipated Near Term Milestones

    13 Anticipated Near Term Milestones TMB - 001 TMB - 002 Q3 2020 Phase 2B – Opening of all sites Phase 2B – Opening of all sites Q4 2020 Reach 50% enrollment of the Phase 2B trial Reach 50% enrollment of the Phase 2B trial Publish data from Phase 2A study Q1 2021 Complete enrollment Complete enrollme

  14. Slide 14: Financial and Capitalization Highlights

    14 Financial and Capitalization Highlights Upon closing of the merger that made Timber a publicly trading company on May 18, 2020, Timber also completed a financing with gross proceeds of $20 million from certain institutional investors in exchange for common shares and warrants. In addition, a $5 m

  15. Slide 15: Leadership Team

    15 Leadership Team Strong Balance between Entrepreneurial Acumen and Proven Operational Leadership Michael Derby, MS, MBA, Executive Chairman • Pharma entrepreneur with several successful exits • Managing Partner of TardiMed Sciences • Founder of Norphan Pharmaceuticals, rare neurology drug developm

  16. Slide 16: Leadership Team (continued)

    16 Zach Rome, Chief Operating Officer • Dermatology inventor and entrepreneur • Co - founder and President at Patagonia Pharmaceuticals, >$11 million in funding from founders and strategic partner • Advanced lead development candidate from concept to Phase 2B clinical studies and was the Recipient o

  17. Slide 17: Summary of Programs and Highlights

    17 ▪ Topical Isotretinoin for Congenital Ichthyosis ▪ Topical Rapamycin for Facial Angiofibromas in Tuberous Sclerosis Complex ▪ Locally Delivered Endothelin - A Antagonist for Localized Scleroderma ▪ Recently acquired Topical Minocycline programs ▪ Label expansion opportunities for all programs ▪ T

  18. Slide 18: Building Bridges in Medical Dermatology

    Building Bridges in Medical Dermatology For additional Investor Information please contact: John Koconis Stephanie Prince CEO PCG Advisory [email protected] [email protected] (646) 762 - 4518 Thank You www.timberpharma.com

Timber Pharmaceuticals — Investor Presentation (September 2020) on 6ix